Management

Paula Ragan, PhD
CEO and President
Dr. Ragan is the Chief Executive Officer and President of X4. She has more than 15 years of experience building companies in the biotechnology industry. Most recently, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc (LTI), an Atlas Venture portfolio company, where she led the company’s business development activities. Prior to LTI, Dr. Ragan held leadership roles in corporate development and operations at Genzyme/Sanofi where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her PhD from MIT and completed post-doctoral studies at Harvard Medical School. Read More
John Celebi
Chief Operating Officer
Mr. Celebi is Chief Operating Officer at X4. He brings a breadth of corporate, business development and operational experience to X4 having spent nearly 20 years in small and large biotechnology companies. Most recently he was the Chief Business Officer at Igenica Biotherapeutics, a company focused on the discovery and development of novel cancer immunotherapies where he led the company’s financing and business development efforts as well as operational activities. Prior to that Mr. Celebi served as vice president of business development, new product planning and alliance management at ArQule, Inc. Mr. Celebi was also a Founder of Cyclis Pharmaceuticals and spent several years in research and business roles at Tularik, Biogen and Agilent Technologies. Mr. Celebi holds an MBA from Carnegie Mellon University and a B.S. in biophysics from the University of California, San Diego. Read More
Sudha Parasuraman, MD
Chief Medical Officer
Dr. Parasuraman is Chief Medical Officer at X4. She brings more than 15 years of industry, academic and community practice experience in hematology, oncology, and pediatrics to drug development. Most recently she served as Vice President, Global Medical Affairs at uniQure Inc, where she worked on gene therapies for rare diseases. Prior to uniQure, she held senior medical positions at Novartis, where she led the early development program for the CDK4/6 inhibitor, ribociclib, and was instrumental in paving the path for accelerated registration studies. She went on to provide medical leadership for a series of innovative clinical trials in the Signature Program and the commercial strategies for early-stage compounds in the portfolio. Dr. Parasuraman also served as Medical Director at Millennium Pharmaceuticals (now Takeda Oncology) where she was the medical lead for several programs including the clinical development and lifecycle management of the first-in-class cancer therapy, Velcade®. Previously, Dr. Parasuraman was a faculty member at Harvard Medical School and was staff physician at Children’s Hospital of Boston, Dana Farber Cancer Institute, and Brigham and Women’s Hospital. Dr. Parasuraman completed her fellowship in pediatric hematology-oncology at St. Jude Children’s Research Hospital in Memphis, TN and pediatric residencies at Children’s Hospital of Michigan and Los Angeles County/University of Southern California Medical Center. She received her medical degree from the University of Madras, India. Read More
Andrea Franz
Chief Financial Officer (consultant)
Ms. Franz is the Chief Financial Officer at X4. She is a financial executive with over 25 years of experience in small to mid-size biotechnology companies. Most recently she was the VP of Finance and Administration at Civitas Therapeutics, Inc where she was instrumental in establishing the infrastructure required for the planned public offering and the resulting sale to Acorda Therapeutics, Inc. Prior to that Ms. Franz served as the interim CFO of Kala Pharmaceuticals during the expansion of the management team and critical financings. Prior to that, Ms. Franz served as the CFO of BIND Biosciences (name changed to BIND Therapeutics) where she was instrumental in building out the financial infrastructure needed from early start-up research to a clinical state oncology company with multiple sources of funding (equity, government, partnerships, debt, public offering). Other prior experience includes projects at Marathon Biopharmaceuticals (purchased by Lonza), Circe Biomedical (purchased by Arbios Systems), Millenium and others. Andrea is a CPA and received her business degree from the University of New Hampshire. Read More
Ronny Mosston, MBA
Vice President of Human Resources
Ms. Mosston is the Vice President of Human Resources at X4. She has held leadership positions in leading biotechnology and life sciences companies for over 20 years in Human Resources and Patient Advocacy/Engagement roles for several leading public bio-technology companies in oncology, rare disease and infertility. In addition to senior positions in Millennium Pharmaceuticals, Takeda, and OvaScience, Ms. Mosston has provided consulting services to the Executive Teams of several leading public and private biotechnology companies to help build their Patient Engagement and Human Resources strategies to align with their business and cultural goals. Prior to working in life sciences, she was a Partner and Chief Operating Officer of a Boston based staffing and executive search company which became publicly traded and was acquired by a top global Human Resources consulting companies. She is the past co-chair and serves on the Dana Farber Patient and Family Advisory Council, the Vice Chair of the Joe Andruzzi Cancer Foundation, a founding member of the MassBIO Patient Advocacy Committee and a member of the Healthcare Businesswomen’s Association (HBA). Ms. Mosston received her BS in Biology and her MBA, in Human Resources Management from Boston University and is active in the community. Read More
Darlene Noci
Vice President, Regulatory Affairs and Quality Assurance
Ms. Noci is Vice President of Regulatory Affairs and Quality Assurance at X4. She has more than 18 years of regulatory experience in small and large biotechnology companies. Most recently, Ms. Noci was Senior Director of Global Regulatory Affairs at EMD Serono. Among other responsibilities, she led the global regulatory strategy for the immune-oncology portfolio which included Avelumab, an anti-PDL1 antibody currently in Phase 3 development. Other professional roles include senior roles in regulatory affairs at Infinity Pharmaceuticals and Genzyme Corporation where she worked in oncology and rare diseases. Ms. Noci received her Masters from Harvard University and a Bachelors at Adelphi University. Read More